Desonide is a topical corticosteroid used for the symptomatic treatment of inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. A nonfluorinated corticosteroid anti-inflammatory agent used topically for dermatoses.
- Mechanism
- Curator reviewed
Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The drug binds to cytosolic glucocorticoid receptors. This complex migrates to the nucleus and binds to genetic elements on the DNA. This activates and represses various genes. However corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
- Primary indication
- For the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatose.Curator reviewed · 4 structured indications
- Formula / weight
- C24H32O6 · 416.5073 g/mol (avg)
- First approval
- Canada, 1993 · United States, 1984
- Also known as
- Desfluorotriamcinolone acetonide
- Code names
- D-2083
- Brand names
Resolves to
WBGKWQHBNHJJPZ-LECWWXJVSA-NSMILES[H][C@@]12C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12CWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Desonide, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account